Department of Reproductive Medicine, Division of Obstetrics, Neonatology and Gynecology, University Medical Center Utrecht, Utrecht, The Netherlands.
Curr Opin Obstet Gynecol. 2010 Jun;22(3):193-201. doi: 10.1097/GCO.0b013e3283384911.
The purpose of this study is to summarize the role of anti-Müllerian hormone (AMH) in assisted reproductive technology (ART) treatment.
AMH is a good marker in the prediction of ovarian response to controlled ovarian hyperstimulation. In clinical practice, this means that AMH may be used for identifying poor or excessive responders. So far, studies show that AMH is not a good predictor for the occurrence of pregnancy after ART treatment. Therefore, routine screening for a poor ovarian reserve status using AMH is not to be advocated. Still, ovarian response prediction using AMH may open ways for patient-tailored stimulation protocols in order to reduce cancellations for excessive response, possibly improve pregnancy prospects and reduce costs.
AMH is able to predict extremes in ovarian response to controlled ovarian hyperstimulation but cannot predict pregnancy after ART treatment. Its future clinical role may be in the individualization of ART stimulation protocols.
本研究旨在总结抗苗勒管激素（AMH）在辅助生殖技术（ART）治疗中的作用。
AMH 是预测控制性卵巢过度刺激反应的良好标志物。在临床实践中，这意味着 AMH 可用于识别卵巢反应不良或过度的患者。到目前为止，研究表明 AMH 并不是 ART 治疗后妊娠发生的良好预测因子。因此，不提倡常规使用 AMH 筛查卵巢储备功能不良。尽管如此，使用 AMH 预测卵巢反应可能为患者定制刺激方案开辟途径，以减少因过度反应而取消治疗的可能性，从而有可能改善妊娠前景并降低成本。
AMH 能够预测控制性卵巢过度刺激反应的极端情况，但不能预测 ART 治疗后的妊娠。其未来的临床作用可能在于 ART 刺激方案的个体化。
